• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ProAssurance Reports Results for First Quarter 2025

    5/6/25 4:15:00 PM ET
    $PRA
    Property-Casualty Insurers
    Finance
    Get the next $PRA alert in real time by email

    ProAssurance Corporation (NYSE:PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported a net loss of $5.8 million, or $0.11 per diluted share, and operating income(1) of $6.8 million, or $0.13 per diluted share, for the three months ended March 31, 2025.

    Highlights(2)

    • First-quarter performance demonstrated continued progress in our efforts to achieve premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets; net results were impacted by non-operating items totaling $12.6 million. Details on those non-operating items can be found under the heading "Reconciliation of Net Income (Loss) to Non-GAAP Operating Income (Loss)" on page 6.
    • Stable net premiums written of $204.5 million for our Medical Professional Liability business, which makes up over 95% of the Specialty P&C segment, were offset by declines in the other business lines in the segment. Net premiums written for the Workers' Compensation Insurance segment were up just $1.3 million.
    • Specialty P&C renewal premium increases of 8% this quarter are part of the over 70% premium change we have accomplished since 2018. Retention for the Specialty P&C segment was a solid 84% for the first quarter of 2025, including 86% for our standard physicians Medical Professional Liability book of business. We continue to forgo renewal and new business opportunities that we believe do not meet our expectation of rate adequacy in the current medical professional liability loss environment. New business for this segment was below last year's first quarter as we focus on risk selection and pricing levels that support progress toward our profitability targets.
    • Consolidated Non-GAAP combined ratio(1) improved 0.3 percentage points over the first quarter of 2024. The Specialty P&C segment's Non-GAAP combined ratio(1) was relatively in line with the prior year while the Workers' Compensation Insurance segment's combined ratio improved by 2.1 percentage points. Management remains focused on ongoing actions to achieve sustained profitability, including price adequacy, disciplined underwriting and cost management.
    • Consolidated net investment income increased 9%, reflecting higher average book yields as we continue to take advantage of the current interest rate environment as well as an increase in average investment balances. Earnings from limited partnership investments (reported as equity in earnings of unconsolidated subsidiaries) also increased, driven by the performance of three LPs/LLCs. These results are typically reported on a one-quarter lag, and the increase reflected higher market valuations during the fourth quarter of 2024.
    • Book value per share was $24.05 at March 31, 2025, up $0.56 from $23.49 at year-end 2024; Non-GAAP adjusted book value per share(1) was $26.68 compared with $26.86 at year end.
    • Announced agreement on March 19, 2025, for The Doctors Company to acquire ProAssurance for $25.00 per share in cash, subject to shareholder and regulatory approval and other customary closing conditions. The transaction is expected to close in the first half of 2026.

    "Our history in medical professional liability has taught us that our focused efforts will be successful over the long-term in this cyclical market," said Ned Rand, President and Chief Executive Officer of ProAssurance. "Joining forces with The Doctors Company through the transaction we announced in March will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities."

    (1)

    Represents a Non-GAAP financial measure that excludes certain items that are not indicative of the performance of our ongoing core operations. See a reconciliation of the Non-GAAP financial measure to its GAAP counterpart under the heading "Non-GAAP Financial Measures" that follows.

    (2)

    Comparisons are to the first quarter of 2024 unless otherwise noted.

     

     

     

     

     

     

    CONSOLIDATED INCOME STATEMENT HIGHLIGHTS

    Selected consolidated financial data for each period is summarized in the table below.

     

    Three Months Ended March 31

    ($ in thousands, except per share data)

    2025

     

    2024

     

    Change

    Revenues

     

     

     

     

     

    Gross premiums written(1)

    $

    303,821

     

     

    $

    311,341

     

     

     

    (2.4

    %)

    Net premiums written

    $

    276,051

     

     

    $

    282,673

     

     

     

    (2.3

    %)

    Net premiums earned

    $

    236,275

     

     

    $

    244,150

     

     

     

    (3.2

    %)

    Net investment income

     

    36,951

     

     

     

    33,897

     

     

     

    9.0

    %

    Equity in earnings (loss) of unconsolidated subsidiaries

     

    4,015

     

     

     

    2,963

     

     

     

    35.5

    %

    Net investment gains (losses)(2)

     

    (1,693

    )

     

     

    (268

    )

     

     

    (531.7

    %)

    Other income (expense)(1)

     

    (3,469

    )

     

     

    3,955

     

     

     

    (187.7

    %)

    Total revenues(1)

     

    272,079

     

     

     

    284,697

     

     

     

    (4.4

    %)

    Expenses

     

     

     

     

     

    Net losses and loss adjustment expenses

     

    189,960

     

     

     

    194,694

     

     

     

    (2.4

    %)

    Underwriting, policy acquisition and operating expenses(1)

     

    83,191

     

     

     

    78,005

     

     

     

    6.6

    %

    SPC U.S. federal income tax expense (benefit)

     

    348

     

     

     

    416

     

     

     

    (16.3

    %)

    SPC dividend expense (income)

     

    (248

    )

     

     

    607

     

     

     

    (140.9

    %)

    Interest expense

     

    5,160

     

     

     

    5,657

     

     

     

    (8.8

    %)

    Total expenses(1)

     

    278,411

     

     

     

    279,379

     

     

     

    (0.3

    %)

    Income (loss) before income taxes

     

    (6,332

    )

     

     

    5,318

     

     

     

    (219.1

    %)

    Income tax expense (benefit)

     

    (510

    )

     

     

    692

     

     

     

    (173.7

    %)

    Net income (loss)

    $

    (5,822

    )

     

    $

    4,626

     

     

     

    (225.9

    %)

    Non-GAAP operating income (loss)(3)

    $

    6,812

     

     

    $

    3,034

     

     

     

    124.5

    %

    Weighted average number of common shares outstanding

     

     

     

     

     

    Basic

     

    51,188

     

     

     

    51,013

     

     

     

    Diluted

     

    51,445

     

     

     

    51,149

     

     

     

    Earnings (loss) per share

     

     

     

     

     

    Net income (loss) per diluted share

    $

    (0.11

    )

     

    $

    0.09

     

     

    $

    (0.20

    )

    Non-GAAP operating income (loss) per diluted share

    $

    0.13

     

     

    $

    0.06

     

     

    $

    0.07

     

    (1)

    Consolidated totals include inter-segment eliminations. The eliminations affect individual line items only and have no effect on net income (loss). See Note 12 of the Notes to Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q for amounts by line item.

    (2)

    This line item typically includes both realized and unrealized investment gains and losses and investment impairments losses. Detailed information regarding the components of net investment gains (losses) are included in Note 3 of the Notes to Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q.

    (3)

    See a reconciliation of net income (loss) to non-GAAP operating results under the heading "Non-GAAP Financial Measures" that follows.

    The abbreviation "nm" indicates that the information or the percentage change is not meaningful.

    BALANCE SHEET HIGHLIGHTS

    ($ in thousands, except per share data)

    March 31, 2025

     

    December 31, 2024

    Total investments

    $

    4,388,982

     

     

    $

    4,367,427

     

    Total assets

    $

    5,526,020

     

     

    $

    5,574,273

     

    Total liabilities

    $

    4,292,400

     

     

    $

    4,372,524

     

    Common shares (par value $0.01)

    $

    639

     

     

    $

    638

     

    Retained earnings

    $

    1,428,903

     

     

    $

    1,434,725

     

    Treasury shares

    $

    (469,694

    )

     

    $

    (469,694

    )

    Shareholders' equity

    $

    1,233,620

     

     

    $

    1,201,749

     

    Book value per share

    $

    24.05

     

     

    $

    23.49

     

    Non-GAAP adjusted book value per share(1)

    $

    26.68

     

     

    $

    26.86

     

    (1)

    Adjusted book value per share is a Non-GAAP financial measure. See a reconciliation of book value per share to Non-GAAP adjusted book value per share under the heading "Non-GAAP Financial Measures" that follows.

    CONSOLIDATED KEY RATIOS

     

    Three Months Ended March 31

     

    2025

     

     

    2024

     

    Current accident year net loss ratio

    80.8

    %

     

    79.9

    %

    Effect of prior accident years' reserve development

    (0.4

    %)

     

    (0.2

    %)

    Net loss ratio

    80.4

    %

     

    79.7

    %

    Underwriting expense ratio

    35.2

    %

     

    31.9

    %

    Combined ratio

    115.6

    %

     

    111.6

    %

    Non-GAAP combined ratio(2)

    112.2

    %

     

    112.5

    %

    Operating ratio

    100.0

    %

     

    97.7

    %

    Non-GAAP operating ratio(2)

    96.4

    %

     

    98.2

    %

    Return on equity(1)

    (1.9

    %)

     

    1.7

    %

    Non-GAAP operating return on equity(1)(2)

    2.2

    %

     

    1.1

    %

    (1)

    Quarterly amounts are annualized. Refer to our March 31, 2025 report on Form 10-Q under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.

    (2)

    Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows.

    SPECIALTY P&C SEGMENT RESULTS

     

     

    Three Months Ended March 31

    ($ in thousands)

    2025

     

    2024

     

     

    % Change

    Gross premiums written

    $

    234,012

     

     

    $

    238,718

     

     

    (2.0

    %)

    Net premiums written

    $

    213,656

     

     

    $

    218,699

     

     

    (2.3

    %)

    Net premiums earned

    $

    183,254

     

     

    $

    188,888

     

     

    (3.0

    %)

    Other income (expense)

     

    3,766

     

     

     

    2,160

     

     

    74.4

    %

    Total revenues

     

    187,020

     

     

     

    191,048

     

     

    (2.1

    %)

    Net losses and loss adjustment expenses

     

    (152,247

    )

     

     

    (152,994

    )

     

    (0.5

    %)

    Underwriting, policy acquisition and operating expenses

     

    (48,635

    )

     

     

    (51,332

    )

     

    (5.3

    %)

    Total expenses

     

    (200,882

    )

     

     

    (204,326

    )

     

    (1.7

    %)

    Segment results

    $

    (13,862

    )

     

    $

    (13,278

    )

     

    (4.4

    %)

    SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS(1)

     

     

    Three Months Ended March 31

     

    2025

     

    2024

    Current accident year net loss ratio

    83.2

    %

     

    82.9

    %

    Effect of prior accident years' reserve development

    (0.6

    %)

     

    (0.9

    %)

    Net loss ratio

    82.6

    %

     

    82.0

    %

    Underwriting expense ratio

    26.4

    %

     

    27.1

    %

    Combined ratio

    109.0

    %

     

    109.1

    %

    (1)

    Represents Non-GAAP financial measures. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows.

    WORKERS' COMPENSATION INSURANCE SEGMENT RESULTS

     

     

    Three Months Ended March 31

    ($ in thousands)

    2025

     

    2024

     

    % Change

    Gross premiums written

    $

    69,809

     

     

    $

    72,615

     

     

    (3.9

    %)

    Net premiums written

    $

    51,606

     

     

    $

    50,353

     

     

    2.5

    %

    Net premiums earned

    $

    41,524

     

     

    $

    41,094

     

     

    1.0

    %

    Other income (expense)

     

    390

     

     

     

    477

     

     

    (18.2

    %)

    Total revenues

     

    41,914

     

     

     

    41,571

     

     

    0.8

    %

    Net losses and loss adjustment expenses

     

    (30,153

    )

     

     

    (31,636

    )

     

    (4.7

    %)

    Underwriting, policy acquisition and operating expenses

     

    (15,603

    )

     

     

    (14,490

    )

     

    7.7

    %

    Total expenses

     

    (45,756

    )

     

     

    (46,126

    )

     

    (0.8

    %)

    Segment results

    $

    (3,842

    )

     

    $

    (4,555

    )

     

    15.7

    %

     

    WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS

     

    Three Months Ended March 31

     

    2025

     

    2024

    Current accident year net loss ratio

    75.0

    %

     

    77.0

    %

    Effect of prior accident years' reserve development

    (2.4

    %)

     

    —

    %

    Net loss ratio

    72.6

    %

     

    77.0

    %

    Underwriting expense ratio

    37.6

    %

     

    35.3

    %

    Combined ratio

    110.2

    %

     

    112.3

    %

     

    SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS

     

    Three Months Ended March 31

    ($ in thousands)

    2025

     

    2024

     

    % Change

    Gross premiums written

    $

    12,748

     

     

    $

    15,934

     

     

    (20.0

    %)

    Net premiums written

    $

    10,789

     

     

    $

    13,621

     

     

    (20.8

    %)

    Net premiums earned

    $

    11,497

     

     

    $

    14,168

     

     

    (18.9

    %)

    Net investment income

     

    816

     

     

     

    693

     

     

    17.7

    %

    Net investment gains (losses)

     

    (335

    )

     

     

    1,471

     

     

    (122.8

    %)

    Other income (expense)

     

    (1

    )

     

     

    (1

    )

     

    —

    %

    Net losses and loss adjustment expenses

     

    (7,560

    )

     

     

    (10,064

    )

     

    (24.9

    %)

    Underwriting, policy acquisition and operating expenses

     

    (4,135

    )

     

     

    (4,713

    )

     

    (12.3

    %)

    SPC U.S. federal income tax (expense) benefit (1)

     

    (348

    )

     

     

    (416

    )

     

    (16.3

    %)

    SPC net results

     

    (66

    )

     

     

    1,138

     

     

    (105.8

    %)

    SPC dividend (expense) income (2)

     

    248

     

     

     

    (607

    )

     

    (140.9

    %)

    Segment results (3)

    $

    182

     

     

    $

    531

     

     

    (65.7

    %)

    (1)

    Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.

    (2)

    Represents the net (profit) loss attributable to external cell participants.

    (3)

    Represents our share of the net profit (loss) and OCI of the SPCs in which we participate.

    SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY

     

    Three Months Ended March 31

     

    2025

     

    2024

    Current accident year net loss ratio

    68.8

    %

     

    65.1

    %

    Effect of prior accident years' reserve development

    (3.0

    %)

     

    5.9

    %

    Net loss ratio

    65.8

    %

     

    71.0

    %

    Underwriting expense ratio

    36.0

    %

     

    33.3

    %

    Combined ratio

    101.8

    %

     

    104.3

    %

     

    CORPORATE SEGMENT

     

     

    Three Months Ended March 31

    ($ in thousands)

    2025

     

    2024

     

    % Change

    Net investment income

    $

    36,135

     

     

    $

    33,204

     

     

    8.8

    %

    Equity in earnings (loss) of unconsolidated subsidiaries:

     

     

     

     

     

    All other investments, primarily investment fund LPs/LLCs

     

    4,070

     

     

     

    3,066

     

     

    32.7

    %

    Tax credit partnerships

     

    (55

    )

     

     

    (103

    )

     

    (46.6

    %)

    Total equity in earnings (loss) of unconsolidated subsidiaries:

     

    4,015

     

     

     

    2,963

     

     

    35.5

    %

    Net investment gains (losses)

     

    (1,358

    )

     

     

    (1,739

    )

     

    21.9

    %

    Other income (expense)

     

    (7,283

    )

     

     

    1,999

     

     

    (464.3

    %)

    Operating expenses(1)

     

    (8,102

    )

     

     

    (8,150

    )

     

    (0.6

    %)

    Interest expense

     

    (5,160

    )

     

     

    (5,657

    )

     

    (8.8

    %)

    Income tax (expense) benefit(1)

     

    (229

    )

     

     

    (692

    )

     

    (66.9

    %)

    Segment results

    $

    18,018

     

     

    $

    21,928

     

     

    (17.8

    %)

    Consolidated effective tax rate

     

    8.1

    %

     

     

    13.0

    %

     

     

    (1)

    Our Corporate segment results for the three months ended March 31, 2025 exclude pre-tax transaction-related costs of $7.1 million and the associated income tax benefit of $0.7 million related to the proposed merger transaction with The Doctors Company as we do not consider these items in assessing the financial performance of the segment. Additional information regarding the proposed merger transaction with The Doctors Company is provided in Note 1 of the Notes to the Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q.

    NON-GAAP FINANCIAL MEASURES

    Non-GAAP Operating Income (Loss)

    Non-GAAP operating income (loss) is a financial measure that is widely used to evaluate performance within the insurance sector. In calculating Non-GAAP operating income (loss), we have excluded the effects of the items listed in the following table that do not reflect normal results. We believe Non-GAAP operating income (loss) presents a useful view of the performance of our ongoing core insurance operations; however, it should be considered in conjunction with net income (loss) computed in accordance with GAAP. The following table is a reconciliation of net income (loss) to Non-GAAP operating income (loss):

     

    RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)

     

    Three Months Ended

    March 31

    ($ in thousands, except per share data)

    2025

     

    2024

    Net income (loss)

    $

    (5,822

    )

     

    $

    4,626

     

    Items excluded in the calculation of Non-GAAP operating income (loss):

     

     

     

    Net investment (gains) losses (1)

     

    1,693

     

     

     

    268

     

    Net investment gains (losses) attributable to SPCs in which no profit/loss is retained (2)

     

    (240

    )

     

     

    1,151

     

    Transaction-related costs (3)

     

    7,057

     

     

     

    —

     

    Foreign currency exchange rate (gains) losses (4)

     

    7,283

     

     

     

    (1,929

    )

    Non-operating income (5)

     

    (2,212

    )

     

     

    —

     

    Guaranty fund assessments (recoupments)

     

    6

     

     

     

    87

     

    Non-core operations (6)

     

    1,124

     

     

     

    (1,143

    )

    Pre-tax effect of exclusions

     

    14,711

     

     

     

    (1,566

    )

    Tax effect, at 21% (7)

     

    (2,077

    )

     

     

    (26

    )

    After-tax effect of exclusions

     

    12,634

     

     

     

    (1,592

    )

    Non-GAAP operating income (loss)

    $

    6,812

     

     

    $

    3,034

     

    Per diluted common share:

     

     

     

    Net income (loss)

    $

    (0.11

    )

     

    $

    0.09

     

    Effect of exclusions

     

    0.24

     

     

     

    (0.03

    )

    Non-GAAP operating income (loss) per diluted common share

    $

    0.13

     

     

    $

    0.06

     

    (1)

    Net investment gains (losses) recognized in earnings are primarily driven by changes in the value of investments that are marked to fair value each period, the nature and timing of which are unrelated to our normal operating results.

    (2)

    Net investment gains (losses) on investments related to SPCs are recognized in our Segregated Portfolio Cell Reinsurance segment. SPC results, including any net investment gain or loss, that are attributable to external cell participants are reflected in the SPC dividend expense (income). To be consistent with our exclusion of net investment gains (losses) recognized in earnings, we are excluding the portion of net investment gains (losses) that is included in the SPC dividend expense (income) which is attributable to the external cell participants.

    (3)

    Transaction-related costs are attributable to professional fees incurred during the first quarter of 2025 in relation to the proposed merger transaction with The Doctors Company. Additional information regarding the proposed merger transaction with The Doctors Company is provided in Note 1 of the Notes to the Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q. We are excluding these costs as they do not reflect normal operating results and are unique and non-recurring in nature.

    (4)

    Foreign currency exchange rate gains (losses) are reported in our Corporate segment and are primarily related to foreign currency denominated loss reserves associated with premium assumed from an international medical professional liability insured in our Specialty P&C segment. Due to the size of this reserve, even nominal movements in exchange rates can lead to volatility in our results of operations. Foreign currency exchange rate losses in the current period also include losses related to the change in fair value of foreign currency forward contracts that were entered into during the quarter. While foreign currency exchange rate movements resulted in volatility in our results of operations, the overall impact on our financial position was nominal due to gains on foreign currency denominated investments that flow through equity. We exclude foreign currency exchange rate movements as the nature and timing of these changes are not indicative of our normal core operating results. Additional information regarding our foreign currency forward contracts is provided in the Executive Summary of Operations section under the heading "Revenues" in our March 31, 2025 report on Form 10-Q.

    (5)

    Non-operating income includes a gain of $2.2 million associated with the sale of our Franklin, TN property to an unrelated third party in the first quarter of 2025 recognized in other income (expense) in our Specialty P&C segment. We are excluding this gain as it does not reflect normal operating results and is unique and non-recurring in nature.

    (6)

    Non-core operations include the net results from operations that are currently in run-off but do not qualify for Discontinued Operations accounting treatment under GAAP. These operations include our Lloyd's Syndicates operations from our previous participation in Syndicate 1729 and Syndicate 6131 as well as our legal professional liability book of business. In April 2025, we sold the renewal rights related to our legal professional liability book of business to an unrelated third party for approximately $1.0 million. Net investment gains (losses) recognized in earnings associated with these operations are included in the adjustment for consolidated net investment gains (losses) as described in footnote 1.

    (7)

    The 21% rate is the annual expected statutory tax rate associated with the taxable or tax deductible items listed above. We utilized the estimated annual effective tax rate method for the three months ended March 31, 2025 and 2024. See further discussion on this method in the Critical Accounting Estimates section under the heading "Estimation of Taxes" and in Note 4 of the Notes to Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q. For both the 2025 and 2024 periods, our effective tax rate was applied to these items in calculating net income (loss), excluding net investment gains (losses) and related adjustments which were treated as discrete items and were tax effected at the annual expected statutory tax rate (21%) in the period they were included in our consolidated tax provision and net income (loss). The taxes associated with the net investment gains (losses) related to SPCs in our Segregated Portfolio Cell Reinsurance segment are paid by the individual SPCs and are not included in our consolidated tax provision or net income (loss); therefore, both the net investment gains (losses) from our Segregated Portfolio Cell Reinsurance segment and the adjustment to exclude the portion of net investment gains (losses) included in the SPC dividend expense (income) in the table above are not tax effected. There are no taxes associated with our Lloyd's Syndicates operations in our consolidated tax provision due to the availability of net operating losses and the full valuation allowance recorded against the deferred tax assets. Accordingly, all adjustments related to our Lloyd's Syndicates operations in the table above are not tax effected. The portion of the transaction-related costs that is tax deductible was tax effected at the statutory tax rate (21%) while the remaining non-deductible portion was not tax effected as there was no associated income tax benefit.

    Non-GAAP Adjusted Key Ratios

    Certain key performance ratios include the impact of certain before-tax effects of items that do not reflect normal operating results, as discussed in the previous table. We believe adjusting our key ratios for these items presents a useful view of the performance of our ongoing core insurance operations; however, it should be considered in conjunction with ratios computed in accordance with GAAP.

    Our consolidated key ratios for the three months ended March 31, 2025 and 2024 include the impact of net underwriting results related to non-core operations, guaranty fund assessments and, for the three months ended March 31, 2025, transaction-related costs (see previous discussion on these items in the table above). Non-core operations include an underwriting loss associated with our Lloyd's Syndicates operations of $1.4 million in the 2025 three-month period as compared to underwriting income of $0.9 million for the same period of 2024. Further, non-core operations include a nominal underwriting loss associated with our legal professional liability book of business in each of the 2025 and 2024 three-month periods.

    The following table is a reconciliation of our consolidated key ratios to Non-GAAP adjusted key ratios for the three months ended March 31, 2025 and 2024:

     

    Three Months Ended March 31

    CONSOLIDATED

    2025

     

    2024

     

    As Reported

    Non-GAAP

    operating

    adjustments

    Non-GAAP

    Adjusted Ratios

     

    As Reported

    Non-GAAP

    operating

    adjustments

    Non-GAAP

    Adjusted Ratios

    Current accident year net loss ratio

    80.8

    %

    0.2 pts

    81.0

    %

     

    79.9

    %

    0.9 pts

    80.8

    %

    Effect of prior accident years' reserve development

    (0.4

    %)

    (0.6 pts)

    (1.0

    %)

     

    (0.2

    %)

    (0.2 pts)

    (0.4

    %)

    Net loss ratio

    80.4

    %

    (0.4 pts)

    80.0

    %

     

    79.7

    %

    0.7 pts

    80.4

    %

    Underwriting expense ratio

    35.2

    %

    (3.0 pts)

    32.2

    %

     

    31.9

    %

    0.2 pts

    32.1

    %

    Combined ratio

    115.6

    %

    (3.4 pts)

    112.2

    %

     

    111.6

    %

    0.9 pts

    112.5

    %

    Less: investment income ratio

    15.6

    %

    0.2 pts

    15.8

    %

     

    13.9

    %

    0.4 pts

    14.3

    %

    Operating ratio

    100.0

    %

    (3.6 pts)

    96.4

    %

     

    97.7

    %

    0.5 pts

    98.2

    %

    Our Specialty P&C segment key ratios for the three months ended March 31, 2025 and 2024 include the impact of net underwriting results related to non-core operations, as previously discussed, and guaranty fund assessments.

    The following table is a reconciliation of our Specialty P&C segment key ratios to Non-GAAP adjusted key ratios for the three months ended March 31, 2025 and 2024:

     

    Three Months Ended March 31

    SPECIALTY P&C SEGMENT

    2025

     

    2024

     

    Segment As

    Reported

    Non-GAAP

    operating

    adjustments

    Non-GAAP

    Adjusted Ratios

     

    Segment As

    Reported

    Non-GAAP

    operating

    adjustments

    Non-GAAP

    Adjusted Ratios

    Current accident year net loss ratio

    82.8

    %

    0.4 pts

    83.2

    %

     

    81.7

    %

    1.2 pts

    82.9

    %

    Effect of prior accident years' reserve development

    0.3

    %

    (0.9 pts)

    (0.6

    %)

     

    (0.7

    %)

    (0.2 pts)

    (0.9

    %)

    Net loss ratio

    83.1

    %

    (0.5 pts)

    82.6

    %

     

    81.0

    %

    1.0 pts

    82.0

    %

    Underwriting expense ratio

    26.5

    %

    (0.1 pts)

    26.4

    %

     

    27.2

    %

    (0.1 pts)

    27.1

    %

    Combined ratio

    109.6

    %

    (0.6 pts)

    109.0

    %

     

    108.2

    %

    0.9 pts

    109.1

    %

    Non-GAAP Operating ROE

    The following table is a reconciliation of ROE to Non-GAAP operating ROE for the three months ended March 31, 2025 and 2024:

     

    Three Months Ended

    March 31

     

    2025

     

    2024

    ROE(1)

    (1.9

    %)

     

    1.7

    %

    Effect of items excluded in the calculation of Non-GAAP operating ROE

    4.1

    %

     

    (0.6

    %)

    Non-GAAP operating ROE

    2.2

    %

     

    1.1

    %

    (1)

    Quarterly amounts are annualized. Refer to our March 31, 2025 report on Form 10-Q under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.

    Non-GAAP Adjusted Book Value per Share

    The following table is a reconciliation of our book value per share to Non-GAAP adjusted book value per share at March 31, 2025 and December 31, 2024:

     

    Book Value Per Share

    Book Value Per Share at December 31, 2024

    $

    23.49

     

    Less: AOCI Per Share(1)

     

    (3.37

    )

    Non-GAAP Adjusted Book Value Per Share at December 31, 2024

     

    26.86

     

    Increase (decrease) to Non-GAAP Adjusted Book Value Per Share during the three months ended March 31, 2025 attributable to:

     

    Net income (loss)

     

    (0.11

    )

    Other(2)

     

    (0.07

    )

    Non-GAAP Adjusted Book Value Per Share at March 31, 2025

     

    26.68

     

    Add: AOCI Per Share(1)

     

    (2.63

    )

    Book Value Per Share at March 31, 2025

    $

    24.05

     

    (1)

    Primarily the impact of accumulated unrealized investment gains (losses) on our available-for-sale fixed maturity investments. See Note 9 of the Notes to Condensed Consolidated Financial Statements in our March 31, 2025 report on Form 10-Q for additional information.

    (2)

    Primarily the impact of an increase in common shares outstanding due to share-based compensation.

    About ProAssurance

    ProAssurance Corporation is an industry-leading specialty insurer with extensive expertise in medical professional liability and products liability for medical technology and life sciences. The Company also is a provider of workers' compensation insurance in the eastern U.S. ProAssurance Group is rated "A" (Excellent) by AM Best.

    For the latest on ProAssurance and its industry-leading suite of products and services, cutting-edge risk management and practice enhancement programs, visit our website at https://ProAssuranceGroup.com with investor content available at https://Investor.ProAssurance.com. Our YouTube channel regularly presents insightful videos that communicate effective practice management, patient safety and risk management strategies.

    Forward-Looking Statements

    The foregoing contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "hope," "hopeful," "likely," "may," "optimistic," "possible," "potential," "preliminary," "project," "should," "will," "would" or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management's current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others: (i) the completion of the proposed transaction on the anticipated terms and timing, (ii) the satisfaction of other conditions to the completion of the proposed transaction, including obtaining required shareholder and regulatory approvals; (iii) the risk that ProAssurance Corporation's stock price may fluctuate during the pendency of the proposed transaction and may decline if the proposed transaction is not completed; (iv) potential litigation relating to the proposed transaction that could be instituted against ProAssurance Corporation or its directors, managers or officers, including the effects of any outcomes related thereto; (v) the risk that disruptions from the proposed transaction will harm ProAssurance Corporation's business, including current plans and operations, including during the pendency of the proposed transaction; (vi) the ability of ProAssurance Corporation to retain and hire key personnel; (vii) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (ix) legislative, regulatory and economic developments; (x) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect ProAssurance Corporation's financial performance; (xi) certain restrictions during the pendency of the proposed transaction that may impact ProAssurance Corporation's ability to pursue certain business opportunities or strategic transactions; (xii) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, outbreaks of war or hostilities or global pandemics, as well as management's response to any of the aforementioned factors; (xiii) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) unexpected costs, liabilities or delays associated with the transaction; (xv) the response of competitors to the transaction; (xvi) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction, including in circumstances requiring ProAssurance Corporation to pay a termination fee ; and (xvii) other risks set forth under the heading "Risk Factors," of our Annual Report on Form 10-K for the year ended December 31, 2024 and in our subsequent filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

    Additional Information and Where To Find It

    This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed acquisition of ProAssurance Corporation by The Doctors Company. In connection with this proposed acquisition, ProAssurance Corporation plans to file one or more proxy statements or other documents with the SEC. This communication is not a substitute for any proxy statement or other document that ProAssurance Corporation has filed or may file with the SEC in connection with the proposed acquisition. INVESTORS AND SECURITY HOLDERS OF PROASSURANCE CORPORATION ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT HAVE BEEN (OR MAY BE) FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Any definitive proxy statement(s) relating to the proposed acquisition (if and when available) will be Delivered to stockholders of ProAssurance Corporation. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by ProAssurance Corporation through the website maintained by the SEC at https://www.sec.gov. Copies of the documents filed with the SEC by ProAssurance Corporation will be available free of charge on ProAssurance Corporation's internet website at https://investor.proassurance.com/SEC-Filings or upon written request to: Investor Relations, ProAssurance Corporation, P.O. Box 590009, Birmingham, Alabama 35259-0009 or by telephone at (205) 776-3028 or (800) 282-6242.

    Participants in Solicitation

    ProAssurance Corporation, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed acquisition. Information about the directors and executive officers of ProAssurance Corporation is set forth in its proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 11, 2025. To the extent that holdings of ProAssurance Corporation's securities by its directors or executive officers have changed since the amounts set forth in ProAssurance Corporation's proxy statement for its 2025 annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250506682069/en/

    For More Information:

    Heather J. Wietzel • SVP, Investor Relations

    800-282-6242 • 205-776-3028 • [email protected]

    Get the next $PRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRA

    DatePrice TargetRatingAnalyst
    4/10/2025Mkt Perform → Underperform
    Raymond James
    4/3/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    11/11/2024$18.00Overweight → Neutral
    Piper Sandler
    2/24/2023$21.00Neutral
    Janney
    8/10/2021$23.00 → $26.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $PRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ProAssurance downgraded by Raymond James

      Raymond James downgraded ProAssurance from Mkt Perform to Underperform

      4/10/25 8:50:33 AM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance downgraded by Citizens JMP

      Citizens JMP downgraded ProAssurance from Mkt Outperform to Mkt Perform

      4/3/25 8:16:49 AM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded ProAssurance from Overweight to Neutral and set a new price target of $18.00

      11/11/24 7:46:20 AM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    Leadership Updates

    Live Leadership Updates

    See more
    • ProAssurance Announces Retirement of PICA Group President, Dr. Ross E. Taubman

      PICA Group, part of the ProAssurance family of companies, announced today the retirement of Dr. Ross E. Taubman, DPM. effective March 31, 2024, after 12 years of dedicated service. During his tenure, Dr. Taubman has been a valuable leader of the PICA Group team, overseeing PICA and OUM since he joined the company in 2011, as well as assuming responsibility as the head of PICA Group's additional business units, DentistCare and LawyerCare, in 2019. Throughout his time as President, Dr. Taubman demonstrated exceptional strategic vision and a passion for innovation. His commitment has helped PICA Group expand its market presence and deliver exceptional results. Under his guidance, PICA has

      8/16/23 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance Declares Quarterly Dividend

      BIRMINGHAM, Ala.--(BUSINESS WIRE)--The Board of Directors of ProAssurance Corporation (NYSE:PRA) has declared a cash dividend of $0.05 per common share, payable on January 7, 2021 to shareholders who own our stock as of December 22, 2020. For 2020, our dividend policy anticipates a total annual dividend of $0.72 per share. On an annualized basis going forward, our policy anticipates annual dividends of $0.20 per share to be paid in equal quarterly installments. However, any decision to pay future cash dividends will be subject to the Board’s final determination after a comprehensive review of the company’s financial performance, future expectations, and other factors deemed relev

      12/2/20 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProAssurance Reports Results for First Quarter 2025

      ProAssurance Corporation (NYSE:PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported a net loss of $5.8 million, or $0.11 per diluted share, and operating income(1) of $6.8 million, or $0.13 per diluted share, for the three months ended March 31, 2025. Highlights(2) First-quarter performance demonstrated continued progress in our efforts to achieve premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets; net results were impacted by non-operating items totaling $12.6 million. Details on those non-operating items can be found under the heading "Re

      5/6/25 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • AM Best Comments on Credit Ratings of ProAssurance Group Members and ProAssurance Corporation Following Announced Acquisition by The Doctors Company Insurance Group

      AM Best has commented that the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of "a+" (Excellent) of the members of ProAssurance Group (ProAssurance) are unchanged following the March 19, 2025, announcement that all outstanding shares of ProAssurance Corporation (PRA) (NYSE:PRA) (Birmingham, AL) will be acquired by The Doctors Company Insurance Group (TDC Group). The outlook of ProAssurance's Credit Ratings (ratings) is stable. The ratings reflect ProAssurance's balance sheet strength, which AM Best assesses as strongest, as well as its adequate operating performance, favorable business profile and appropriate enterprise risk management. ProAssurance is

      3/19/25 5:17:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • AM Best Comments on Credit Ratings of The Doctors Company Insurance Group Members Following Announced Acquisition of ProAssurance Corporation

      AM Best has commented that the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the members of The Doctors Company Insurance Group (TDC Group) (Napa, CA) are unchanged following the March 19, 2025, announcement that TDC Group will acquire all outstanding shares of ProAssurance Corporation (PRA) (NYSE:PRA) (Birmingham, AL). The outlook of TDC Group's Credit Ratings (ratings) is stable. The ratings reflect TDC Group's balance sheet strength, which AM Best assesses as strongest, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. TDC Group is the second-la

      3/19/25 5:04:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive VP/Chief HR Officer Dishart Noreen exercised 10,165 shares at a strike of $16.13 and covered exercise/tax liability with 3,888 shares, increasing direct ownership by 62% to 16,479 units (SEC Form 4)

      4 - PROASSURANCE CORP (0001127703) (Issuer)

      2/26/25 5:36:06 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • Chief Financial Officer Hendricks Dana S exercised 13,064 shares at a strike of $16.13 and covered exercise/tax liability with 5,781 shares, increasing direct ownership by 30% to 31,239 units (SEC Form 4)

      4 - PROASSURANCE CORP (0001127703) (Issuer)

      2/26/25 5:35:53 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • Pres Healthcare Pro. Liability Francis Robert David exercised 10,997 shares at a strike of $16.19 and covered exercise/tax liability with 4,647 shares, increasing direct ownership by 66% to 15,973 units (SEC Form 4)

      4 - PROASSURANCE CORP (0001127703) (Issuer)

      2/26/25 5:35:41 PM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProAssurance Corporation

      SC 13G/A - PROASSURANCE CORP (0001127703) (Subject)

      11/14/24 1:28:29 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • SEC Form SC 13G filed by ProAssurance Corporation

      SC 13G - PROASSURANCE CORP (0001127703) (Subject)

      2/14/24 10:04:34 AM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • SEC Form SC 13G filed by ProAssurance Corporation

      SC 13G - PROASSURANCE CORP (0001127703) (Subject)

      2/9/24 9:59:03 AM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by ProAssurance Corporation

      DEFA14A - PROASSURANCE CORP (0001127703) (Filer)

      5/7/25 4:21:01 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • SEC Form 10-Q filed by ProAssurance Corporation

      10-Q - PROASSURANCE CORP (0001127703) (Filer)

      5/6/25 4:21:53 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROASSURANCE CORP (0001127703) (Filer)

      5/6/25 4:17:42 PM ET
      $PRA
      Property-Casualty Insurers
      Finance

    $PRA
    Financials

    Live finance-specific insights

    See more
    • ProAssurance Reports Results for First Quarter 2025

      ProAssurance Corporation (NYSE:PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported a net loss of $5.8 million, or $0.11 per diluted share, and operating income(1) of $6.8 million, or $0.13 per diluted share, for the three months ended March 31, 2025. Highlights(2) First-quarter performance demonstrated continued progress in our efforts to achieve premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets; net results were impacted by non-operating items totaling $12.6 million. Details on those non-operating items can be found under the heading "Re

      5/6/25 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance Reports Results for Fourth Quarter and Full-Year 2024

      ProAssurance Corporation (NYSE:PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability and a core small-cap value equity in the financials sector, today reported net income of $16.2 million, or $0.31 per diluted share, and operating income(1) of $18.3 million, or $0.36 per diluted share, for the three months ended December 31, 2024. For full-year 2024, ProAssurance reported net income of $52.7 million, or $1.03 per diluted share, and operating income(1) of $48.6 million, or $0.95 per diluted share. Fourth Quarter 2024(2) Highlights Specialty P&C segment combined ratio(1) of 100.9% demonstrates another quarter of progress from management's

      2/24/25 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance
    • ProAssurance to Announce Fourth-Quarter and Full-Year 2024 Results on Monday, February 24, 2025

      Investor call to be held at 10:00 a.m. ET on Tuesday, February 25 ProAssurance Corporation (NYSE:PRA) will issue its news release and file its Form 10-K after the market closes on Monday, February 24, 2025. The release and 10-K will be available on the Company's website at investor.proassurance.com. ProAssurance will conduct its Fourth-Quarter and Full-Year 2024 quarterly conference call with analysts and investors to discuss the results and other information on Tuesday, February 25, 2025, at 10:00 a.m. ET. Preregistration for the call is available here and the dial-in numbers are (833) 470-1428 (toll free) or (404) 975-4839, access code 927016. Investors are encouraged to listen to t

      2/13/25 4:15:00 PM ET
      $PRA
      Property-Casualty Insurers
      Finance